康泰生物：经各方审慎评估与协商，决定终止与阿斯利康设立合资公司事项

Core Viewpoint - The company has decided to terminate the strategic partnership with AstraZeneca for vaccine development due to significant market changes and high risks associated with new investments in the vaccine industry [1] Group 1: Partnership Details - The company previously planned to establish a joint venture with AstraZeneca, focusing on vaccine development [1] - The total investment for the joint venture was estimated to be approximately $400 million (around 2.76 billion RMB), with both parties holding 50% equity [1] Group 2: Market Conditions - The industry is currently facing considerable downward pressure due to drastic changes in the market environment [1] - A careful assessment and negotiation among all parties led to the decision to terminate the partnership [1]